Patents by Inventor Maximiliano Vasquez

Maximiliano Vasquez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibodies to fibroblast growth factor receptor 2
    Patent number: 9382324
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: July 5, 2016
    Assignee: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Antibody libraries
    Patent number: 9354228
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: May 31, 2016
    Assignee: Adimab, LLC
    Inventors: Maximiliano Vasquez, Arvind Sivasubramanian, Michael Feldhaus
  • ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R)
    Publication number: 20160046719
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Inventors: Justin Wong, Maximiliano Vasquez
  • Nucleic acids encoding antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 9200075
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: December 1, 2015
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Justin Wong, Maximiliano Vasquez
  • Endoglin antibodies
    Patent number: 9150652
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: October 6, 2015
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • ANTIBODY MOLECULES TO TIM-3 AND USES THEREOF
    Publication number: 20150218274
    Abstract: Antibody molecules that specifically bind to TIM-3 are disclosed. The anti-TIM-3 antibody molecules can be used to treat, prevent and/or diagnose immune, cancerous, or infectious conditions and/or disorders.
    Type: Application
    Filed: January 30, 2015
    Publication date: August 6, 2015
    Inventors: Catherine Anne Sabatos-Peyton, Barbara Brannetti, Alan S. Harris, Thomas Huber, Thomas Pietzonka, Jennifer Marie Mataraza, Walter A. Blattler, Daniel J. Hicklin, Maximiliano Vasquez, Rosemarie H. DeKruyff, Dale T. Umetsu, Gordon James Freeman, Tiancen Hu, John A. Taraszka, Fangmin Xu
  • Humanized PAI-1 Antibodies and Uses Thereof
    Publication number: 20150010536
    Abstract: The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof.
    Type: Application
    Filed: November 22, 2013
    Publication date: January 8, 2015
    Applicant: CisThera, Incorporated
    Inventors: Donald E. Staunton, Maximiliano Vasquez
  • RATIONALLY DESIGNED, SYNTHETIC ANTIBODY LIBRARIES AND USES THEREFOR
    Publication number: 20140364340
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
    Type: Application
    Filed: January 8, 2014
    Publication date: December 11, 2014
    Applicant: ADIMAB, LLC
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • Humanized Monoclonal Antibodies to Hepatocyte Growth Factor
    Publication number: 20140335076
    Abstract: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: January 8, 2014
    Publication date: November 13, 2014
    Applicant: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Maximiliano Vasquez
  • Rationally designed, synthetic antibody libraries and uses therefor
    Patent number: 8877688
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: November 4, 2014
    Assignee: Adimab, LLC
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R)
    Publication number: 20140322757
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Application
    Filed: April 30, 2014
    Publication date: October 30, 2014
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Justin Wong, Maximiliano Vasquez
  • ENDOGLIN ANTIBODIES
    Publication number: 20140314742
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Application
    Filed: October 15, 2013
    Publication date: October 23, 2014
    Applicant: TRACON PHARMACEUTICALS, INC.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
    Publication number: 20140221250
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system, with or without DH segments derived from other species, and are based on rational design informed by examination of publicly available databases of antibody sequences.
    Type: Application
    Filed: April 18, 2014
    Publication date: August 7, 2014
    Applicant: Adimab, LLC
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2
    Publication number: 20140193899
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Application
    Filed: November 4, 2013
    Publication date: July 10, 2014
    Applicant: GALAXY BIOTECH, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Methods of treatment by administering antibodies that bind colony stimulating factor 1 receptor (CSF1R)
    Patent number: 8747845
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: June 10, 2014
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Justin Wong, Maximiliano Vasquez
  • Rationally designed, synthetic antibody libraries and uses therefor
    Patent number: 8691730
    Abstract: The present invention overcomes the inadequacies inherent in the known methods for generating libraries of antibody-encoding polynucleotides by specifically designing the libraries with directed sequence and length diversity. The libraries are designed to reflect the preimmune repertoire naturally created by the human immune system and are based on rational design informed by examination of publicly available databases of human antibody sequences.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: April 8, 2014
    Assignee: Adimab, LLC
    Inventors: Maximiliano Vasquez, Michael Feldhaus, Tillman U. Gerngross, K. Dane Wittrup
  • Humanized monoclonal antibodies to hepatocyte growth factor
    Patent number: 8628778
    Abstract: The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: January 14, 2014
    Assignee: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Hangil Park, Lihong Wang, Maximiliano Vasquez
  • Endoglin antibodies
    Patent number: 8609094
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: December 17, 2013
    Assignee: Tracon Pharmaceuticals, Inc.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • Monoclonal antibodies to fibroblast growth factor receptor 2
    Patent number: 8603987
    Abstract: The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: December 10, 2013
    Assignee: Galaxy Biotech, LLC
    Inventors: Kyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
  • Humanized antibodies that sequester amyloid beta peptide
    Patent number: 8591894
    Abstract: A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A? peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A?.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: November 26, 2013
    Assignees: Eli Lilly and Company, Washington University
    Inventors: David M Holtzman, Ronald DeMattos, Kelly R. Bales, Steven M. Paul, Naoya Tsurushita, Maximiliano Vasquez